(Q50586380)

16 March 2018

title

Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. (English)

1 reference

16 March 2018

1 reference

1 reference

Solís-Herruzo JA

1

1 reference

16 March 2018

Castellano G

2

1 reference

16 March 2018

Fernández I

3

1 reference

16 March 2018

Muñoz R

4

1 reference

16 March 2018

Hawkins F

5

1 reference

16 March 2018

publication date

1 November 2000

1 reference

16 March 2018

published in

Journal of Hepatology

1 reference

16 March 2018

volume

33

1 reference

16 March 2018

issue

5

1 reference

16 March 2018

page(s)

812-817

1 reference

16 March 2018

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Therapy of hepatitis C: alpha interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980314-1

7 January 2021

10.1016/S0168-8278(00)80314-1

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018